Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group.
Ramos F, Robledo C, Pereira A, Pedro C, Benito R, de Paz R, Del Rey M, Insunza A, Tormo M, Díez-Campelo M, Xicoy B, Salido E, Sánchez-Del-Real J, Arenillas L, Florensa L, Luño E, Del Cañizo C, Sanz GF, María Hernández-Rivas J; Spanish Group for Myelodysplastic Syndromes (GESMD). Ramos F, et al. Among authors: del canizo c. Am J Hematol. 2017 Sep;92(9):E534-E541. doi: 10.1002/ajh.24813. Epub 2017 Jul 19. Am J Hematol. 2017. PMID: 28612357 Free article. Clinical Trial.
Myelodysplastic syndrome: a search for minimal diagnostic criteria.
Ramos F, Fernández-Ferrero S, Suárez D, Barbón M, Rodríguez JA, Gil S, Megido M, Ciudad J, López N, del Cañizo C, Orfao A. Ramos F, et al. Among authors: del canizo c. Leuk Res. 1999 Mar;23(3):283-90. doi: 10.1016/s0145-2126(98)00166-0. Leuk Res. 1999. PMID: 10071083
Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the national institutes health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapy.
Pérez-Simón JA, Encinas C, Silva F, Arcos MJ, Díez-Campelo M, Sánchez-Guijo FM, Colado E, Martín J, Vazquez L, Del Cañizo C, Caballero D, San Miguel J. Pérez-Simón JA, et al. Among authors: del canizo c. Biol Blood Marrow Transplant. 2008 Oct;14(10):1163-1171. doi: 10.1016/j.bbmt.2008.07.015. Biol Blood Marrow Transplant. 2008. PMID: 18804047 Free article.
Liver function tests and absolute lymphocyte count at day +100 are predictive factors for extensive and severe chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplant.
Silva F, Pérez-Simón JA, Caballero Velazquez T, Encinas C, Sánchez-Guijo FM, Díez-Campelo M, Colado E, Martín J, Villanueva-Gomez F, Vazquez L, Del Cañizo C, Caballero D, San Miguel J. Silva F, et al. Among authors: del canizo c. Am J Hematol. 2010 Apr;85(4):290-3. doi: 10.1002/ajh.21613. Am J Hematol. 2010. PMID: 20162543 Free article. No abstract available.
Cytogenetic risk stratification in chronic myelomonocytic leukemia.
Such E, Cervera J, Costa D, Solé F, Vallespí T, Luño E, Collado R, Calasanz MJ, Hernández-Rivas JM, Cigudosa JC, Nomdedeu B, Mallo M, Carbonell F, Bueno J, Ardanaz MT, Ramos F, Tormo M, Sancho-Tello R, del Cañizo C, Gómez V, Marco V, Xicoy B, Bonanad S, Pedro C, Bernal T, Sanz GF. Such E, et al. Among authors: del canizo c. Haematologica. 2011 Mar;96(3):375-83. doi: 10.3324/haematol.2010.030957. Epub 2010 Nov 25. Haematologica. 2011. PMID: 21109693 Free PMC article.
Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome.
Cordoba I, González-Porras JR, Nomdedeu B, Luño E, de Paz R, Such E, Tormo M, Vallespi T, Collado R, Xicoy B, Andreu R, Muñoz JA, Solé F, Cervera J, del Cañizo C; Spanish Myelodysplastic Syndrome Registry. Cordoba I, et al. Among authors: del canizo c. Cancer. 2012 Jan 1;118(1):127-33. doi: 10.1002/cncr.26279. Epub 2011 Jun 29. Cancer. 2012. PMID: 21717439 Free article.
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.
Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M, Muus P, Te Boekhorst P, Sanz G, Del Cañizo C, Guerci-Bresler A, Nilsson L, Platzbecker U, Lübbert M, Quesnel B, Cazzola M, Ganser A, Bowen D, Schlegelberger B, Aul C, Knight R, Francis J, Fu T, Hellström-Lindberg E; MDS-004 Lenalidomide del5q Study Group. Fenaux P, et al. Among authors: del canizo c. Blood. 2011 Oct 6;118(14):3765-76. doi: 10.1182/blood-2011-01-330126. Epub 2011 Jul 13. Blood. 2011. PMID: 21753188 Free article. Clinical Trial.
[Myelodysplastic syndrome in the elderly: comprehensive geriatric assessment and therapeutic recommendations].
López Arrieta JM, De Paz R, Altés A, del Cañizo C; Sociedad Española de Medicina Geriátrica; Sociedad Española de Hematología y Hemoterapia. López Arrieta JM, et al. Among authors: del canizo c. Med Clin (Barc). 2012 Feb 18;138(3):119.e1-9. doi: 10.1016/j.medcli.2011.08.003. Epub 2011 Oct 26. Med Clin (Barc). 2012. PMID: 22032819 Spanish.
70 results